Skip to main content
Home
language-selector-globe Global | en
Choose Location
  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | English
Novartis Foundation | English
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Turkey | Türk
United Kingdom | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe Global
Choose Location
International Americas Asia Pacific Europe Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Turkey | Türk
United Kingdom | English
United States | English
    • About 
      • Board of Directors 
        • Joerg Reinhardt 
        • Simon Moroney 
        • Nancy C. Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Charles L. Sawyers 
        • William T. Winters 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Klaus Moosmayer 
        • Lutz Hegemann 
        • Mukul Mehta 
        • Kees Roks 
        • Michelle Weese 
      • Strategy 
        • People and Culture 
        • Data and Digital 
      • Products 
      • Novartis Gene Therapies 
      • Therapeutic areas 
        • Hematology 
        • Neuroscience 
        • Solid tumors 
      • Diversity, Equity & Inclusion 
        • Equity 
        • Diversity, Equity & Inclusion Governance and Community 
        • Inclusivity 
        • Parental Leave 
        • Society 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis Quality Management System (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and Recognition 
      Male scientist in lab

      About

      Learn about how Novartis is organized and our strategy, vision and mission. Meet our people and read about our commitments to diversity, equity and inclusion. Explore our history which goes back more than 250 years.

    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient Organization Funding 
      • Stories: Patients Perspectives 
      Couple holding hands

      Patients and Caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare Professionals 
      • Medical Congresses and Events 
        • Abstract summaries for EULAR 
        • Abstract summaries for ACR 
        • ASCO Annual Meeting 
      • Products 
      • Novartis Pipeline 
      • Managed Access Programs 
        • Novartis Gene Therapies Managed Access Program 
      • Novartis External Funding 
      • Healthcare Professional Resources by Country 
      • Investigator-Initiated Trials / Studies 
      • Transparency and Disclosure 
      • Novartis Medical Information 
        • Submit medical enquiry 
      Doctor

      Healthcare Professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research & Development 
      • Biomedical Research 
        • Collaborations 
        • Novartis Global Scholars Program 
      • Technology Platforms 
      • Research Disease Areas 
        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
        • Ophthalmology research at Novartis 
      • Novartis Pipeline 
      • Translational Medicine 
      • Research Collaborations 
      • Open Source Science 
      • Stories from our Labs 
      Scientists conducting innovative research experiments

      Research & Development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-Based Pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis Access Principles 
        • Novartis Oncology Access 
        • Patents and Licensing 
      • Ethics, Risk and Compliance 
        • Ethical Behavior 
        • Compliance 
        • Human Rights 
        • Learning and Engagement 
        • Risk management 
      • Environmental Sustainability 
        • Climate 
        • Waste 
        • Water 
      • Global Health 
        • Pandemic Preparedness 
        • Avoidable Blindness 
        • Chagas Disease 
        • Leprosy 
        • Malaria 
        • Sickle Cell Disease (SCD) 
        • Novartis Foundation 
      • Diversity, Equity & Inclusion 
      • Reporting 
        • ESG Rating Performance 
        • Codes, Policies and Guidelines 
        • Materiality Assessment 
        • Transparency and Disclosure 
        • Targets 
        • Positions 
      • ESG Index 
      Young patients waiting outside an hospital in Rwanda

      Environmental, Social and Governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 
      • Event Calendar 
      • Financial Data 
        • Novartis Annual Results 
        • Novartis Quarterly Results 
        • Novartis SEC Filings 
        • Product Sales 
        • Fixed-Income Securities 
        • Expected Currency Impact 
      • Share Data & Analysis 
        • Share Monitor 
        • Dividend Information 
        • Share Ownership 
        • Share Overview 
        • Return On Investment Calculator 
      • Shareholder Information 
        • General Meetings 
        • American Depository Receipts (ADR) 
        • Share Buy-Back 
        • Frequently Asked Questions 
      • Company Overview 
        • Corporate Governance 
      • Novartis Annual Reporting Suite 
        • Reporting Archive 
        • Publications Order Form 
      • ESG 
      Hands marking a test tube

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 
      • News Archive  
      • Media Library  
      • Stories 
      • Subscribe 
      People at the table with screens

      News

      Information for journalists including media releases, statements, stories, multimedia resources and more.

    • Careers 
      • Career Search 
      • Benefits & Rewards 
      • Career Programs 
        • Community Exploration & Learning Lab (CELL) 
        • Postdoc Program 
      • Early Careers 
        • Careers in Data, Digital & Information Technology (IT) 
        • Careers in Technical Operations 
        • Students 
        • Graduates 
        • US NIBR Internship Programs 
      • Personal Growth 
      • Wellbeing 
      Close-up portrait of a scientist in Cambridge, USA

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical Trials 
      doctor taking the blood pressure of her patient

      Clinical Trials

      Find recruiting clinical trials and learn more about how to participate or work with Novartis on clinical studies. Read about our clinical trials transparency initiatives.

    • Partnering 
      Corporate & Business Development

      Partnering

      Learn about our approach to partnering which combines capabilities, collaboration and culture.

    • Supplier Portal 
      Group of business people in a meeting area

      Supplier Portal

      Practical information and resources for suppliers around the world.

    • Report side effects 
      Our Mission

      Report side effects

      Let us know about any unwanted medical occurrences.

    • Contacts 
      Office Cubicle

      Contacts

      Get in touch.

    Chemist working in a lab in Cambridge

    Home

    Welcome to Novartis where we are reimagining medicine to improve and extend people’s lives.

Placeholder Image

Ophthalmology

Tags Archive Navigation
  • All
  • Careers
  • Featured News
  • In the News
  • Media Releases
  • Story
icon
  • Media Release
    Aug 15, 2023
    Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
  • Media Release
    Jun 30, 2023
    Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
  • Clos up photography of a boy
    Featured News
    Oct 13, 2022
    World Sight Day 2022: Raising awareness on the importance of eye health
  • Media Release
    Mar 31, 2022
    Novartis announces European Commission approval of Beovu® for people living with diabetic macular edema
  • Media Release
    Dec 22, 2021
    Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
  • Media Release
    Oct 13, 2021
    Novartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema
  • Teenager getting eyes tested
    Featured News
    Oct 14, 2021
    World Sight Day 2021
  • Story
    Oct 13, 2021
    Restoring vision and hope to thousands in Southeast Asia
  • Media Release
    Aug 17, 2021
    Novartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeks
  • Media Release
    Sep 21, 2021
    Novartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können
  • Media Release
    Sep 21, 2021
    Novartis acquiert Arctos Medical, élargissant ainsi son portefeuille d’optogénétique afin de proposer des thérapies géniques aux patients souffrant d’une sévère perte de la vision
  • Media Release
    Sep 21, 2021
    Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss

Pagination

  • 1
  • 2
  • 3
  • › Next page

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • ESG
  • SpeakUp
Explore
  • Novartis Pipeline
  • Products
  • Therapeutic areas
  • Diseases
  • Stories
  • Locations
Novartis companies
  • Advanced Accelerator Applications
  • Chinook Therapeutics
  • Gyroscope Therapeutics
Footer Bottom
© 2023 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience